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Prostaglandin E2 (PGE2) is an important lipid mediator in inflammatory and
immune responses during acute and chronic infections. Upon stimulation by various
proinflammatory stimuli such as lipopolysaccharide (LPS), interleukin (IL)-1β, and
tumor necrosis factor (TNF)-α, PGE2 synthesis is upregulated by the expression of
cyclooxygenases. Biologically active PGE2 is then able to signal through four primary
receptors to elicit a response. PGE2 is a critical molecule that regulates the activation,
maturation, migration, and cytokine secretion of several immune cells, particularly those
involved in innate immunity such as macrophages, neutrophils, natural killer cells, and
dendritic cells. Both Gram-negative and Gram-positive bacteria can induce PGE2 synthesis
to regulate immune responses during bacterial pathogenesis. This review will focus on
PGE2 in innate immunity and how bacterial pathogens influence PGE2 production during
enteric and pulmonary infections. The conserved ability of many bacterial pathogens to
promote PGE2 responses during infection suggests a common signaling mechanism
to deter protective pro-inflammatory immune responses. Inhibition of PGE2 production
and signaling during infection may represent a therapeutic alternative to treat bacterial
infections. Further study of the immunosuppressive effects of PGE2 on innate immunity
will lead to a better understanding of potential therapeutic targets within the PGE2
pathway.
Keywords: bacteria, prostaglandin, COX, immunotherapeutic, mucosal, infection
INTRODUCTION
Prostaglandin E2 (PGE2) is an important lipid mediator in
inflammatory and immune responses during acute and chronic
infections (Phipps et al., 1991; Yu and Chadee, 1998; Harris
et al., 2002; Nagamatsu and Schust, 2010). Upon stimulation
by various proinflammatory stimuli such as lipopolysaccharide
(LPS), interleukin (IL)-1β, and tumor necrosis factor (TNF)-α,
PGE2 synthesis is upregulated by the expression of one of three
cyclooxygenases (Filion et al., 2001; Kis et al., 2006; Park et al.,
2006). Biologically active PGE2 is then able to signal through
four primary receptors to elicit a response (Sugimoto et al.,
1992; Honda et al., 1993; Nishigaki et al., 1996; Hata and Breyer,
2004). Molecular concentrations of PGE2 and receptor signaling
are both influential in regulating proinflammatory and immuno-
suppressive immune cell phenotypes (Kalinski, 2012). PGE2 is a
critical molecule that regulates the activation, maturation, migra-
tion, and cytokine secretion of several immune cells, particularly
those involved in innate immunity such as macrophages, neu-
trophils, natural killer cells, and dendritic cells (Bankhurst, 1982;
Goto et al., 1983; Kalin´ski et al., 1997; Yu and Chadee, 1998;
Aronoff et al., 2004; Serezani et al., 2007; Nagamatsu and Schust,
2010). Both Gram-negative and Gram-positive bacteria can
induce PGE2 synthesis to regulate immune responses during bac-
terial pathogenesis (Harris et al., 2002; Hessle et al., 2003). This
review will focus on PGE2 in innate immunity and how bacterial
pathogens influence PGE2 production during enteric and pul-
monary infections. Inhibition of PGE2 production, recognition,
and signaling may lead to therapeutic alternatives to regulate
the innate immune response during bacterial infection. Active
mechanisms utilized by bacteria may also promote PGE2 synthe-
sis during pathogenesis. Examination of these mechanisms could
elicit a better understanding of disease progression and infection
outcome.
PGE2 PRODUCTION
While PGE2 can be produced by all cell types, immune cells
are a primary source of PGE2 production during an inflam-
matory response (Kalinski, 2012). Within these cells, PGE2 is
derived from the release of arachidonic acid (AA) from cell mem-
branes by phospholipase A2 (PLA2) enzymes. While there are
multiple members within the PLA2 family, the most utilized
enzyme for PGE2 synthesis is the cytosolic calcium-dependent
PLA2 (cPLA2) (Lambeau and Lazdunski, 1999). Subsequently,
one of two primary cyclooxygenases utilizes AA as a substrate
to produce the biological precursor prostaglandin H2 (PGH2).
The two cyclooxygenases available for this reaction are COX-1
(constitutively active at basal levels) and COX-2 (highly inducible
by inflammatory cytokines and growth factors) (Phipps et al.,
1991). PGE2 is then enzymatically produced as an end prod-
uct of the reaction with the aid of PGE2 synthase (PGES) (Park
et al., 2006). Biologically active PGE2 can then readily signal
through one of four eicosanoid receptors (EP) (Figure 1). The
rate of PGE2 production during an immune response is primarily
believed to be dependent upon the expression and activity of
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FIGURE 1 | Modulation of PGE2 by pathogenic bacteria. PGE2 synthesis
is initiated by the release of AA from the lipid cell membrane by the
enzyme cPLA2. Either COX-1 (constitutively expressed) or COX-2
(inducible) can utilize AA as a substrate to produce the precursor PGH2.
PGH2 is converted to biologically active PGE2 by means of the enzyme
PGE2 synthase. PGE2 can then readily signal through one of four EP,
denoted EP1, EP2, EP3, and EP4. Various pathogens influence PGE2
production and signaling along different steps of this pathway. Green
arrows indicate activation of COX-2 or PGES, while red lines indicate
inhibition of COX-2 or PGES by select pathogens. Blue lines indicate a
potential role for EP signaling in pathogen survival.
COX-2 (Kalinski, 2012), thus it is an important enzyme on which
to focus when examining PGE2. PGE2 is relatively stable in vitro,
yet is rapidly degraded in tissues by 15-hydroxyprostaglandin
dehydrogenase (15-PGDH) (Fitzpatrick et al., 1980; Tai et al.,
2002). Accordingly, in order to examine PGE2 under biological
conditions, it is necessary to account for its rate of production
via COX-2 and PGES and its degradation in response to different
stimuli.
PGE2 RECEPTOR SIGNALING
There are four known PGE2 receptors designated EP1, EP2, EP3,
and EP4, with at least three splice variants of EP3 recognized as
EP3α, EP3β, and EP3γ. This diversity of PGE2 receptors influ-
ences the pro-inflammatory and immunosuppressive functions
of this molecule within the body under different environmental
conditions. EP3 and EP4 are considered to be high-affinity recep-
tors, requiring lower levels of PGE2 for signaling. Conversely, EP1
and EP2 demand higher concentrations of PGE2 for proper sig-
naling. Additionally, the four PGE2 receptors vary in their signal
durations (Sugimoto et al., 1992; Honda et al., 1993; Nishigaki
et al., 1996; Hata and Breyer, 2004). While the PGE2 receptors
have fundamental differences in affinity and signal durations,
there are mechanistic similarities between some of these recep-
tors. For example, EP2 and EP4 are both Gs-coupled receptors
that signal primarily through the adenylate cyclase-dependent
cAMP/PKA/CREB pathways. EP2 and EP4 are the predominant
receptors responsible for the anti-inflammatory and immuno-
suppressive effects of PGE2 (Fujino et al., 2005). Both receptors
are primarily thought to function in a cAMP-dependent man-
ner, however EP4 also signals in a phosphatidylinositol 3-kinase
(PI3K)-dependent manner to activate the extracellular-signal-
regulated kinase 1/2 (ERK1/2) pathway (Fujino et al., 2003).
Conversely, EP1 and EP3 do not require cAMP for activation. Few
studies have examined the low-affinity EP1, although PGE2 sig-
naling through this receptor leads to an increase in the release of
cellular calcium (Hata and Breyer, 2004). Signaling through EP3
primarily involves Gi-coupled receptors that inhibit the activity
of adenylate cyclase, and consequently decrease levels of cAMP in
the cell. Nevertheless, EP3 splice variants are also able to signal
through Gs-coupled receptors, enhancing the diverse signaling
ranges among these PGE2 receptors (Sugimoto et al., 1992).
The diversity of receptors, signaling pathways, and signal dura-
tion enables PGE2 to act as an adaptable signaling molecule in
a wide range of cell types in response to environmental stimuli.
The complexities of PGE2 signaling help address its paradoxi-
cal ability to elicit both inflammatory and immunosuppressive
responses under various concentrations and environmental con-
ditions at early and late stages of bacterial infection (Hessle
et al., 2003; Stefanelli et al., 2012). Furthermore, while PGE2-
mediated immunoregulation is essential for maintaining home-
ostasis, the immunosuppressive effects of PGE2 during innate
immune responses may be detrimental during bacterial infection,
as examined in depth below.
PGE2 AND INNATE IMMUNITY
Neutrophils
Neutrophils are the first leukocytes recruited to sites of infec-
tion during an innate immune response. These cells possess
several immune defense mechanisms including phagocytosis,
proteolytic enzymes, oxygen-reactive agents, and inflammatory
mediators. Accordingly, proper migration as well as signaling
between these granulocytes and other immune cells is impor-
tant to allow for an effective immune response at early stages
of infection. Activation and aggregation of human neutrophils
is inhibited after exogenous treatment with PGE2 in vitro (Ney
and Schrör, 1991; Wheeldon and Vardey, 1993; Talpain et al.,
1995). PGE2 also inhibits the activation of rat and guinea pig neu-
trophils in vitro, suggesting a conserved inhibitory role of PGE2
signaling among mammalian immune responses (Ham et al.,
1983; Takenawa et al., 1986; Wise and Jones, 1994; Wise, 1996).
Activation of mammalian neutrophils by formylmethionyl-
leucyl-phenylalanine (fMLP) is inhibited by PGE2 in an EP2-
dependent manner (Takenawa et al., 1986; Burelout et al., 2004,
2007). Inhibition of EP2 signaling improves neutrophil migra-
tion to promote bacterial clearing and enhances mouse survival
following intratracheal infection with Pseudomonas aeruginosa
(Sadikot et al., 2007; Aronoff et al., 2012). Bacterial pathogens and
their structural components directly promote PGE2 synthesis by
neutrophils during infections. For example, Streptococcus pneu-
moniae infection induces PGE2 production by humanneutrophils
and obstructs activation and migration in vitro (Cockeran et al.,
2001). Neutrophils also produce increased concentrations of
PGE2 after treatment with E. coli LPS or post-infection with P.
aeruginosa in rat and mouse models, respectively (He et al., 2001;
Alba-Loureiro et al., 2004). Since neutrophils represent a first
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line of defense against infection, it is important to further elu-
cidate PGE2 production during bacterial infection and examine
its immunomodulatory effects on the antimicrobial functions of
neutrophils.
Macrophages
Through phagocytosis and the generation of a strong cytokine
response, macrophages are important cells in innate immune
responses and immunomodulation. While PGE2 is able to locally
attract macrophages at early stages of inflammation (Nakayama
et al., 2006), macrophage activation can be inhibited by PGE2
through EP2 signaling (Zaslona et al., 2012). The phagocytic
properties of alveolar macrophages are inhibited in an EP2-
dependent manner during infection with Klebsiella pneumoniae
and S. pneumoniae in the rat and mouse models, respectively.
Phagocytosis is restored through the inhibition of PGE2 syn-
thesis with non-selective COX inhibitors such as indomethacin
(Aronoff et al., 2004; Aronoff, 2012). The phagocytic properties
of macrophages are dampened by PGE2 through the induc-
tion of immunosuppressive IL-1R-associated kinase-M (IRAK-
M), impairing bacterial clearance of P. aeruginosa (Hubbard
et al., 2010). PGE2 also affects the inflammatory response of
macrophages during infection by altering cell signaling and
inhibiting bactericidal mechanisms. Upon PGE2 stimulation,
NAPDH oxidase is inhibited inside the macrophage, leading to
reduced killing of K. pneumoniae (Serezani et al., 2007). PGE2
also suppresses macrophage activity by inhibiting the production
of nitric oxide radicals (Marotta et al., 1992; Asakrah et al., 2013).
PGE2 alters the cytokine response of macrophages and promotes
an immunosuppressive phenotype. Most notable perhaps is that
PGE2 induces the production of immunoregulatory cytokines,
such as IL-10 and IL-17 (Kunkel et al., 1986, 1988; Huang
et al., 1998; Stolina et al., 2000; Liu et al., 2012). Phosphatase
and tensin homolog deleted on chromosome 10 (PTEN) is a
downstream product of PGE2 signaling that negatively regulates
alveolar macrophage phagocytosis and bacterial killing during
P. aeruginosa infection. Inhibition or genetic knockout of PTEN
restores the phagocytic functions of macrophages and enhances
bacterial clearance in vivo (Hubbard et al., 2010).
Natural killer cells
Natural killer (NK) cells are potent granulocytes important in
controlling infection during innate immune responses. While NK
cells are most commonly associated with controlling viral infec-
tions, they are also important during bacterial infection. These
cells respond to changes in the cytokine profile during infection
in order to lyse infected cells, and PGE2 has a negative effect on
the cytolytic activities of NK cells by suppressing their respon-
siveness to cytokines such IL-12 and IL-15 (Bankhurst, 1982;
Goto et al., 1983; Joshi et al., 2001; Walker and Rotondo, 2004).
In a leukemia rat model, an increase in PGE2 concentration is
associated with diminished NK cell cytolysis and decreased ani-
mal survival, which is relieved upon COX inhibition by etodolac
(Inbar et al., 2011). NK cells also secrete IFN-γ as a signaling
mechanism to activate macrophages during the innate immune
response and to aid dendritic cells in driving Th1 responses.
PGE2 suppresses NK cell-mediated activation of macrophages
by inhibiting the production of IFN-γ (Mailliard et al., 2005).
Not only does PGE2 have an inhibitory effect on the cytokine
response of NK cells, but it also downregulates the expression
of receptors important for NK cell effector functions, includ-
ing CD94/NKG2C, DNAM-1, NKp80, 2B4, and CD161. PGE2
also has a deleterious effect on the homing, migration, and sur-
vival of NK cells in humans infected with Human Herpes Virus 8
who have developed Kaposi’s sarcoma (Dupuy et al., 2012). This
demonstrates similarity to PGE2’s ability to negatively affect the
aggregation of neutrophils, suggesting that there may be a con-
served signaling mechanism across immune cell types. Further
research must be conducted in order to elucidate the effect of
PGE2 on NK cell activity during bacterial infection.
Dendritic cells
Dendritic cells (DCs) process and present antigen to immune
cells during innate and adaptive immune responses and are
consequently important in controlling disease progression and
outcome. They initiate an adaptive immune response and are
key participants in shifting immunity between Th1 and Th2
responses. PGE2 can disrupt DC differentiation at early stages of
development (Kalin´ski et al., 1997). At later stages of DC differen-
tiation, PGE2 can hasten DC maturation in the presence of IL-1β
and TNF-α (Rieser et al., 1997; Kalin´ski et al., 1998). DCs that
are fully developed, but functionally immature are prompted by
PGE2 to migrate to lymph nodes (Jonuleit et al., 1997). Enhanced
DC migration may be due to the ability of PGE2 to induce the
expression of the lymphoid-homing chemokine receptor CCR7
on DCs (Luft et al., 2002; Scandella et al., 2002; Kalinski, 2012).
However, PGE2 suppresses the production of chemokines, such as
the CCR7 ligand CCL19, by DCs and inhibits naïve T cell attrac-
tion in the lymph nodes (Muthuswamy et al., 2010). PGE2 also
impairs the ability of DCs to induce NK cell-mediated immunity
(Gustafsson et al., 2008). These contrasting DC characteristics
may be in part due to differences in PGE2 concentrations as
well as receptor signaling. While it is generally accepted that
DCs matured in the presence of PGE2 promote T cell expansion,
these particular DCs suppress Th1 responses and support Th2
responses (Kalinski, 2012). For example, while PGE2-matured
DCs effectively prime naïve T cells (Jonuleit et al., 1997), they also
suppress the cytotoxic T lymphocyte (CTL) response (Obermajer
et al., 2011). This alteration may be in part due to a trans-
formed cytokine profile of PGE2-matured DCs. In particular,
DCs matured in the presence of PGE2 display an enhanced pro-
duction of immunosuppressive cytokines such as IL-10 (Kalin´ski
et al., 1997) and suppress their own production of proinflam-
matory cytokines such as IL-12p70 (Kalin´ski et al., 1998). By
shifting cytokine profiles away from a Th1 and toward a Th2
response, PGE2 may in fact promote the maturation of DCs that
are better-suited to allow for intracellular bacteria to establish
infection.
THE ROLE OF PGE2 DURING BACTERIAL INFECTION
Multiple bacterial pathogens elicit an increase in PGE2 pro-
duction upon infection. Both Gram-negative and Gram-positive
bacteria are able to induce PGE2 synthesis, yet Gram-negative
bacteria elicit a stronger PGE2 response by human monocytes
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(Hessle et al., 2003). While passive recognition of LPS can con-
tribute to PGE2 production in response to Gram-negative bac-
teria (Alba-Loureiro et al., 2004), it is becoming apparent that
bacteria also actively induce PGE2 production during infection.
Levels of PGE2 are highly regulated in the lung and gastroin-
testinal tract to maintain the integrity of the mucosal barrier
(Takeuchi et al., 2010; Bozyk andMoore, 2011), and bacteria may
modulate PGE2 biosynthesis to aid colonization of the lung and
gut. In fact, enhanced PGE2 synthesis by immune cells appears
to be a conserved event during bacterial infections within the
mucosa, and this will be discussed in the following sections.
ENTERIC INFECTIONS
Salmonella
Salmonella is a Gram-negative facultative intracellular bacillus
that is able to infect and survive inside several cell types includ-
ing intestinal epithelial cells and macrophages. Several serotypes
of Salmonella including S. enterica, S. dublin, and S. typhimurium
induce the expression on PGE2 during infection (Ochman et al.,
1996; Eckmann et al., 1997; Uchiya and Nikai, 2004). One
of Salmonella’s most well-characterized virulence factors is the
pathogenicity island 2 (SPI-2). This pathogenicity island is nec-
essary for growth within the macrophage and is an important
virulence factor in establishing infection in mice (Ochman et al.,
1996; Cirillo et al., 1998; Hensel et al., 1998). SpiC, an important
gene product encoded within SPI-2, is necessary for survival of S.
typhimuriumwithinmacrophages (Uchiya et al., 1999). SpiC acti-
vates the ERK1/2 signal transduction pathway to enhance COX-2
expression and PGE2 synthesis in infected macrophages, indicat-
ing that Salmonella possesses active mechanisms to alter host cell
signaling in intestinal epithelial cells which enhances PGE2 pro-
duction (Resta-Lenert and Barrett, 2002; Uchiya andNikai, 2004).
Salmonella-induced PGE2 activates the protein kinase A (PKA)
pathway and upregulates IL-10 production by macrophages, pro-
moting an immunosuppressive phenotype and impaired killing
ability. COX inhibition by indomethacin or SC-58125 restores
the bactericidal properties of macrophages during Salmonella
infection in vitro (Uchiya and Nikai, 2004). PGE2 production
is also dependent upon the expression of Salmonella DNA ade-
nine methylase (dam). Salmonella dam mutants are unable to
promote COX-2 expression, leading to reduced PGE2 produc-
tion in infected murine macrophages (Cristina Cerquetti et al.,
2008). Along with the inability to elicit a strong PGE2 response,
dam mutants are less cytotoxic toM cells, deficient in cell
invasion (García-Del Portillo et al., 1999), and confer cross-
protective Salmonella immunity in a mouse model (Heithoff
et al., 2001).
During experimental salmonellosis with S. typhimurium,
COX-2 expression and PGE2 concentrations in macrophages and
dendritic cells within the mesenteric lymph nodes remain ele-
vated 3 days after intragastric infection in the mouse model. At
early stages of acute infection in the mouse model, COX-2 inhi-
bition with celecoxib leads to an increase in bacterial loads in
the mesenteric lymph nodes; however, at later stages of infection,
COX-2 inhibition enhances host survival (Bowman and Bost,
2004). Thus, while PGE2 may have beneficial proinflammatory
properties during acute Salmonella infection, prolonged exposure
to PGE2 may be detrimental and promote an environment
susceptible to chronic disease.
Escherichia coli
Enteropathogenic E. coli (EPEC) and enterohemorrhagic E. coli
(EHEC) are Gram-negative bacteria that colonize the intes-
tine and cause diarrheal disease. Both EPEC and EHEC induce
PGE2 production by intestinal epithelial cells, however the most
potent inducers of PGE2 are invasive strains such as E. coli
O29:NM (Eckmann et al., 1997). The Type 3-secreted effec-
tor EspT is a guanine nucleotide exchange factor important
for EPEC cellular invasion. EPEC strains expressing EspT pro-
mote increased COX-2 expression and PGE2 production by
infected macrophages (Raymond et al., 2011). This suggests
PGE2 increases in part through EspT expression and does not
rely entirely on passive immune recognition of LPS or other
Toll-like receptor (TLR) agonists, such as flagellin. This also
suggests bacteria utilize active signaling mechanisms to exploit
PGE2 for intracellular survival. High concentrations of E. coli
LPS also induce PGE2 production by macrophages (Kurland and
Bockman, 1978; Rosenstreich et al., 1978). E. coli LPS adminis-
tered at 40mg/kg is 100% fatal in the normal mouse model, yet
COX-2−/− mice demonstrate 100% survival at this dosage and
are significantly protected against LPS doses as high as 100mg/kg
(Ejima et al., 2003). Accordingly, COX-2 inhibitionmay represent
a therapeutic strategy in controlling infection with pathogenic
E. coli.
Other enteric species
It is not surprising that additional enteric pathogens are able
to elicit a PGE2 response upon infection. Vibrio cholerae is an
enteric bacterial pathogen whose infection leads to acute watery
diarrhea and an increase in PGE2 secretion in infected intesti-
nal tissues. Specifically, jejunal fluids from patients presenting
with acute cholera infection contain increased concentrations
of PGE2 (Speelman et al., 1985). Both children and adults
infected with V. cholerae O1 and V. cholerae O139 demonstrate
significantly higher concentrations of PGE2 in stools when com-
pared to healthy controls during the acute stages of infection.
However, there is no significant difference in plasma PGE2 lev-
els in these patients, suggesting the PGE2 response is restricted
to the infected mucosa (Qadri et al., 2002). Cholera toxin (CT)
also influences PGE2 production, as murine macrophages display
enhanced PLA2 activity and PGE2 synthesis when stimulated with
exogenous CT (Burch et al., 1988). Similarly, stimulation of iso-
lated intestinal rabbit cells with CT leads to an increase in PGE2
concentrations (Peterson et al., 1994).
Other enteric bacterial pathogens demonstrate an ability to
induce PGE2 production by infected cells. Both pediatric and
adult patients presenting with acute shigellosis exhibit signif-
icantly higher concentrations of PGE2 in stool samples when
compared to healthy controls (Raqib et al., 2000). Further stud-
ies must be conducted in order to determine the mechanisms
by which enteric pathogens elicit PGE2 production in infected
cells. Moreover, it will be necessary to determine how PGE2 con-
centrations affect both the host immune response and bacterial
pathogenesis at various stages of enteric infection.
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PULMONARY INFECTIONS
Mycobacteria
Mycobacteria are acid-fast bacilli that cause progressive or latent
pulmonary disease after aerosol inhalation (Torrado et al., 2011).
Several Mycobacteria species induce PGE2 production during
infection. In the mouse model, M. intracellulare induces PGE2
synthesis, inhibiting the production of lymphokines in infected
macrophages and suppressing an effective immune response
(Edwards et al., 1986). M. bovis bacillus Calmette-Guerin (BCG)
also enhances COX-2 expression and PGE2 production in a
TLR2-dependent manner in infected macrophages in vitro and
in a mouse model (Bansal et al., 2009). In particular, the pres-
ence of PGE2 has been noted in the sera and cerebrospinal fluid
of tuberculosis patients (Bansal et al., 2009). Mice infected with
M. tuberculosis demonstrate a 13-fold increase in lung PGE2
levels at 30 days post-infection compared to uninfected mice
(Peres-Buzalaf et al., 2011). Granuloma formation, a hallmark
of tuberculosis infection, is comprised of macrophages exhibit-
ing high levels of COX-2 expression and PGE2 synthesis in the
mouse model (Rangel Moreno et al., 2002). A gene encoding
early secreted antigenic target protein 6 (ESAT-6), present in all
pathogenic strains of Mycobacterium, induces COX-2 expression
and PGE2 production in a TLR2-dependent manner in infected
macrophages in vitro (A et al., 2012). Interestingly, the avirulent
M. tuberculosis stain H37Ra was shown to promote macrophage
PGE2 production leading to cellular apoptosis, while the viru-
lent strain H37Rv induced significantly less PGE2 and caused
macrophage necrosis (Chen et al., 2008; Divangahi et al., 2009).
PGES−/− macrophages are unable to control H37Rv replication
and PGES−/− mice demonstrate significantly higher bacterial
burdens at 5 weeks post-infection with virulent M. tuberculosis,
suggesting that PGE2 is necessary to control M. tuberculosis dur-
ing the early stage of infection (Chen et al., 2008). Similar results
were reported by Rangel Moreno et al. (2002) using wild type
mice infected with H37Rv. COX-2, PGES, and PGE2 expression
were low and relatively stable during the early phase of infec-
tion (up to 21 days), and COX-2 inhibition during early infection
led to increased bacterial growth and immunopathology. In con-
trast, COX-2, PGES, and PGE2 expression increased during the
chronic phase of infection (60–90 days), and inhibition of COX-2
led to increased iNOS expression with a concomitant reduction
in lung bacterial load and granuloma size (Rangel Moreno et al.,
2002). Clearly modulation of PGE2 can impact disease outcome
during M. tuberculosis infection, and the consequences of PGE2
inhibition may differ between acute and chronic stages of tuber-
culosis infection. Therapeutic strategies targeting PGE2 may lead
to alternative therapies in controlling Mycobacterium infection in
the lung.
Streptococcus
Community-acquired pneumonia is one of the leading causes of
death worldwide (Finch, 2001), and is most commonly caused
by S. pneumoniae (Mandell et al., 2007). In patients suffer-
ing from acute pneumonia, COX-2 is expressed in alveolar
epithelial cells (AECs). Similarly, AECs, alveolar macrophages,
and vascular endothelial cells of human lung tissue in vitro
exhibit time-dependent increases in both COX-2 expression and
PGE2 production post-infection with S. pneumoniae (Szymanski
et al., 2012). Streptococcal toxins also promote PGE2 pro-
duction in immune cells. Particularly, pneumolysin produced
by S. pneumoniae promotes the production of PGE2 in neu-
trophils and endothelial cells by inducing the expression of PLA2
(Rubins et al., 1994; Cockeran et al., 2001). Enhanced PGE2
production by neutrophils treated with pneumolysin inhibits
an effective immune response by obstructing neutrophil acti-
vation and migration (Takenawa et al., 1986; Cockeran et al.,
2001; Burelout et al., 2004, 2007). Inhibiting PGE2 produc-
tion during Streptococcus infection enhances macrophage phago-
cytosis and generation of reactive oxygen species, aiding in
bacterial clearance (Stables et al., 2010). PGE2 signaling post-
Streptococcus infection relies on both EP2 and EP4 signaling
(Aronoff et al., 2012; Szymanski et al., 2012). EP2−/− murine
alveolar macrophages demonstrate enhanced phagocytosis, intra-
cellular killing, and increased generation of reactive oxygen
in vitro, while EP2−/− mice demonstrate improved bacterial
clearance and survival post-infection with S. pneumoniae. Animal
survival may be associated with a heightened production of pro-
inflammatory cytokines, such as IL-12p40 (Aronoff et al., 2012).
EP3 also plays a large role in PGE2 signaling post-infection
with Streptococcus both in vitro and in a mouse model. EP3−/−
macrophages in vitro have enhanced phagocytic properties and
bacterial killing mechanisms, such as nitric oxide production.
EP3−/− mice also exhibit greater levels of protection against
S. pneumoniae when compared to wildtype mice. Specifically,
EP3−/− mice demonstrate heightened bacterial clearance in the
lung by alveolar macrophages, with a decrease in infiltrating lung
neutrophils and blood leukocytes (Aronoff et al., 2009). The
immunosuppressive qualities of PGE2 have characteristically been
attributed to EP2 and EP4 signaling, but EP3 signaling also con-
tributes to increased production of PGE2 during pneumococcal
infection.
Other species of Streptococcus induce an increase in PGE2 syn-
thesis during pulmonary infection as well. Group B Streptococcus
is a leading cause of neonatal sepsis and pneumonia, and infec-
tion with this bacterial pathogen leads to enhanced expression
of COX-2 and increased concentrations of PGE2 in A549 human
lung epithelial cells (Glibetic et al., 2001; Natarajan et al., 2007).
S. pyogenes, a causative agent of pharyngitis, induces the expres-
sion of COX-2 and PGE2 synthesis in the macrophages of tis-
sue biopsies from infected patients as well as in infected mice.
Pharmacological inhibition of PGE2 synthesis by PKI (14–22)
or genetic ablation of COX-2 expression promotes bacterial
clearance and improves disease outcome in the mouse model
(Goldmann et al., 2010).
Pseudomonas aeruginosa
P. aeruginosa is one of the most virulent opportunistic pathogens
and is the leading cause of morbidity and mortality in cystic
fibrosis patients (Sato et al., 2003; Sadikot et al., 2005). P. aerug-
inosa is also a common cause of hospital-acquired pneumonia
(Sadikot et al., 2005). In a murine model of P. aeruginosa infec-
tion, overproduction of PGE2 in the lung diminishes phagocy-
tosis and TNF-α production by alveolar macrophages (Ballinger
et al., 2006; Hubbard et al., 2010). The inhibitory effects of
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PGE2 appear to partially signal through EP2, as EP2−/− mice
demonstrate decreased bacterial loads post-infection (Sadikot
et al., 2007). P. aeruginosa induces cPLA2 activity within infected
A549 epithelial cells in an ERK 1/2-dependent manner to trig-
ger a four-fold increase in PGE2 production, which can be
suppressed with the use of a specific cPLA2 inhibitor (Hurley
et al., 2011). COX-2-deficient mice display enhanced bacterial
clearance post-infection when compared to wildtype control
mice. Recruitment of inflammatory cells in COX-2-deficient
mice does not differ from those of control mice post-infection,
suggesting bacterial clearance is associated with impaired effec-
tor functions of immune cells (Sadikot et al., 2007). Inhibition
of COX-2 expression also decreases the severity of P. aerug-
inosa infection and increases survival rates in mice (Saliba
et al., 2005; Sadikot et al., 2007). Murine bone marrow-derived
macrophages treated with the selective COX-2 inhibitor NS-398
prior to infection with P. aeruginosa have lower concentrations
of PGE2 and show an increase in superoxide production post-
infection when compared tomock-treated controls (Sadikot et al.,
2005).
Other pulmonary species
Burkholderia pseudomallei is a facultative intracellular
Gram- negative bacillus that causes a fatal disease known as
melioidosis. Patients acquire the infection through different
routes and can present with a wide range of clinical symptoms
including debilitating pneumonia and septic shock (Cheng and
Currie, 2005). Recent work from our laboratory has demon-
strated that PGE2 plays a critical role in the pathogenesis of
B. pseudomallei infection in mice (Asakrah et al., 2013). PGE2
promotes B. pseudomallei intracellular survival through the
activation of arginase 2 which competes with inducible nitric
oxide synthase for the substrate, L-arginine, thereby limiting
nitric oxide production. This process is antagonized by block-
ing PGE2 synthesis with a selective COX-2 inhibitor, NS398
(Asakrah et al., 2013). Treatment of bone marrow-derived
macrophages with NS398 reduces endogenous PGE2 produc-
tion and intracellular survival of B. pseudomallei. Conversely,
addition of exogenous PGE2 to NS398-treated macrophages
restores B. pseudomallei survival. Administration of NS-398 or
Celecoxib significantly enhances mouse survival from lethal
pulmonary infection with B. pseudomallei (Asakrah et al.,
2013).
Burkholderia cepacia is a Gram-negative bacterium that causes
fatal lung infections in cystic fibrosis patients. Approximately
20% of infected patients have severe pulmonary epithelial dete-
rioration that can lead to death within a matter of weeks (Isles
et al., 1984). In human lung epithelial cells, B. cepacia promotes
enhanced PGE2 synthesis, possibly increasing the severity of dis-
ease in immunocompromised individuals (Fink et al., 2003).
Bordatella pertussis infections result in a severe pulmonary illness
known as pertussis or “whooping cough.” Pertussis toxin (PT)
stimulates an increase in PGE2 production in infected murine
macrophages in vitro (Burch et al., 1988; Schulze-Specking et al.,
1991). Further research is warranted to identify the mechanisms
behind which various pulmonary pathogens modulate PGE2
responses in the lung in order to aid infection.
ACTIVE INDUCTION OF PGE2
When inactivated, many bacteria are unable to elicit a strong
PGE2 response by host cells. For example, when compared
to live bacteria, UV-irradiated S. typhimurium are unable to
induce COX-2 expression in infected macrophages, suggesting
that Salmonella uses active mechanisms to alter gene expres-
sion in infected tissues for the production of PGE2 (Bowman
and Bost, 2004). Similarly, UV-irradiated S. aureus are unable
to promote PGE2 biosynthesis in infected osteoblasts (Somayaji
et al., 2008). Both live and gamma-irradiated M. avium induce
PGE2 production in infected human peripheral blood monocyte-
derived macrophages, yet gamma-irradiated M. avium induce
significantly lower concentrations of PGE2 (Rastogi et al., 1992).
Heat inactivation of B. pseudomallei also led to a significant
reduction in COX-2 expression and PGE2 production by murine
macrophages (Asakrah et al., 2013). The reduced ability of inac-
tivated bacteria to elicit a strong PGE2 response during infection
suggests these bacteria have evolved active mechanisms to alter
host cell signaling to promote PGE2 synthesis that may aid
infection.
Type three secretion systems (T3SS) are important bacterial
secretion systems, some of which stimulate PGE2 production dur-
ing bacterial pathogenesis (Sato et al., 2003; Saliba et al., 2005;
Sadikot et al., 2007; Raymond et al., 2011). ExoU is a T3SS
effector molecule associated with P. aeruginosa infections which
lead to nosocomial pneumonia and bacteremia (Berthelot et al.,
2003; Schulert et al., 2003). This cytotoxin possesses phospho-
lipase activity and induces rapid AA release from the cell wall
and enhances PGE2 production during the infection of human
epithelial cells (Sato and Frank, 2004; Saliba et al., 2005; Sadikot
et al., 2007). Mice infected with ExoU-deficient P. aeruginosa have
a significant decrease in COX-2 expression and diminished PGE2
production in the lung and a lower bacterial load in infected tis-
sue, indicating that the secretion of this effector molecule aids in
establishing infection (Saliba et al., 2005; Sadikot et al., 2007). E.
coli also utilizes a T3SS effector molecule, EspT, to elicit a PGE2
response in infected macrophages (Raymond et al., 2011). Taken
together, these studies highlight a conserved mechanism among
bacterial T3SSs that induce PGE2 production during infection,
and elucidation of these effectors may identify new therapeutic
targets.
PGE2 AS A POTENTIAL THERAPEUTIC TARGET DURING
BACTERIAL INFECTION
COX-2 INHIBITION
Since PGE2 production has inhibitory effects on immune cells,
particularly those involved in innate immune responses, inhi-
bition of PGE2 may benefit the host during bacterial infection
(Goto et al., 1983; Kunkel et al., 1986; Phipps et al., 1991;
Strassmann et al., 1994; Kalin´ski et al., 1997; Harris et al.,
2002). In support of this, mice deficient in COX-2 demon-
strate enhanced survival post-infection with several bacterial
pathogens. For example, COX-2−/− mice exposed intraperi-
toneally to high doses of E. coli endotoxin exhibit increased
survival compared to wildtype mice (Ejima et al., 2003). COX-2-
deficient mice also demonstrate greater survival rates and exhibit
lower bacterial loads in the liver and spleen after intravenous
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infection with S. pyogenes (Bowman and Bost, 2004). When com-
pared to wildtype mice, COX-2−/− mice exhibit increased bacte-
rial clearance and enhanced survival at 6 days post-intratracheal
infection with P. aeruginosa (Sadikot et al., 2007).
COX inhibitors, which are already widely used in the human
population for the relief of pain and inflammation, block the
production of PGE2 and other prostaglandins and may offer
therapeutic benefit during bacterial infections. For example, non-
selective COX inhibitors such as ibuprofen and indomethacin,
significantly reduce the bacterial load and PGE2 production in
the bronchoalveolar lavage (BAL) after intratracheal P. aerugi-
nosa infection in mice (Saliba et al., 2005). COX-2 inhibition
by NS-398 also significantly improves mouse survival post-
intratracheal infection with lethal doses of P. aeruginosa (Sadikot
et al., 2007). Moreover, NS398 administered post-exposure to
mice infected with B. pseudomallei significantly reduces lung
PGE2 levels and enhances animal survival (Asakrah et al., 2013).
COX-2 inhibition results in higher bacterial loads during acute
S. typhimurium and M. tuberculosis infection in mouse mod-
els, however administration of a COX-2 inhibitor during chronic
infection with S. typhimurium or M. tuberculosis improves host
protection (Rangel Moreno et al., 2002; Bowman and Bost,
2004). Similarly, Celecoxib treatment reduces lung levels of PGE2
and enhances the 60-day survival of M. tuberculosis-infected
mice (Peres-Buzalaf et al., 2011). Because COX-2 inhibition
impairs the production of prostaglandins in addition to PGE2,
it is important to consider the potential contribution of other
prostaglandins in such studies. Furthermore, additional studies
in highly relevant animal models are needed to determine the
therapeutic efficacy of COX inhibitors against mucosal bacterial
infections.
RECEPTOR INHIBITION
Specific targeting of one or more PGE2 receptors may also hold
therapeutic promise. EP2 is a major receptor responsible for the
immunosuppressive activities of PGE2 signaling (Fujino et al.,
2005). EP2−/− alveolar macrophages exhibit improved phago-
cytosis, increased production of reactive oxygen intermediates
and pro-inflammatory cytokines, such as TNF-α and MIP-2, and
enhanced killing of P. aeruginosa (Aronoff et al., 2012). Impaired
EP2 signaling improves disease outcome in P. aeruginosa-infected
mice, as EP2-deficient mice show enhanced survival and bac-
terial clearance correlated with enhanced neutrophil migration
and IL-12 production in the lung (Sadikot et al., 2007; Aronoff
et al., 2012). Inhibition of EP3 may also be beneficial in con-
trolling bacterial infections. EP3-deficient alveolar macrophages
demonstrate increased phagocytic activity and nitric oxide pro-
duction, and enhanced bacterial killing during S. pneumoniae
infection. EP3−/− mice exhibit greater bacterial clearance and
higher survival post-intraperitoneal infection (Aronoff et al.,
2009). Specific EP inhibitors or antagonists may aid in ther-
apeutically controlling microbial infection and require further
study.
CONCLUSIONS AND FUTURE DIRECTIONS
PGE2 is an important lipid mediator that regulates inflamma-
tion and immune responses during infection (Phipps et al.,
1991; Yu and Chadee, 1998; Harris et al., 2002; Nagamatsu and
Schust, 2010). Four principle PGE2 receptors respond to varying
concentrations of PGE2 in order to elicit dynamic downstream
signaling events during immune responses. It is increasingly
evident that PGE2 biosynthesis and its inhibitory actions on
innate immune defenses can impact bacterial pathogenesis and
disease outcome. For infected macrophages, PGE2 production
correlates with diminished phagocytosis, nitric oxide produc-
tion, and intracellular killing (Marotta et al., 1992; Aronoff
et al., 2004; Hubbard et al., 2010), and promotes an immuno-
suppressive cytokine profile (Kunkel et al., 1986, 1988; Huang
et al., 1998; Stolina et al., 2000; Liu et al., 2012). Neutrophil
and NK cell activation, migration, and aggregation are inhib-
ited by PGE2 (Bankhurst, 1982; Goto et al., 1983; Takenawa
et al., 1986; Joshi et al., 2001; Burelout et al., 2004, 2007; Walker
and Rotondo, 2004). PGE2 shifts the immune response away
from a Th1 response and toward a Th2 response by promot-
ing the production of anti-inflammatory cytokines and mod-
ulating the interactions between DCs and other immune cells
(Kalin´ski et al., 1997, 1998; Gustafsson et al., 2008; Obermajer
et al., 2011). The conserved ability of many bacterial pathogens
to promote PGE2 responses during infection suggests a com-
mon signaling mechanism to deter protective pro-inflammatory
immune responses. Inhibition of PGE2 production and signal-
ing during infection may represent a therapeutic alternative to
treat certain bacterial infections. Further study of the immuno-
suppressive effects of PGE2 on innate immunity will lead to a
better understanding of potential therapeutic targets within the
PGE2 pathway.
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